Amneal Pharmaceuticals delivered a strong third quarter in 2025, with net revenue increasing by 12% to $785 million compared to the previous year. The company achieved a GAAP net income of $2 million and diluted income per share of $0.01. Adjusted EBITDA rose by 1% to $160 million, and adjusted diluted EPS increased by 6% to $0.17, reflecting growth across all segments and strategic product launches.

Amneal Pharmaceuticals delivered a strong second quarter in 2025, with net revenue increasing by 3% to $725 million and GAAP net income rising significantly to $22 million from $6 million in the prior year. The company also reported a substantial increase in Adjusted EBITDA and Adjusted Diluted EPS, driven by strong performance across its segments and successful debt refinancing.

Amneal Pharmaceuticals, Inc. delivered a strong first quarter in 2025, with broad-based growth across all three segments. Net revenue increased by 5% to $695 million, and net income attributable to Amneal Pharmaceuticals, Inc. was $12 million, a significant improvement from a net loss in the prior year. Adjusted EBITDA also saw a 12% increase, reaching $170 million.

Amneal Pharmaceuticals posted Q4 2024 revenue of $731 million, an 18% increase from Q4 2023, driven by growth in all business segments. The company reported a net loss of $31 million, significantly lower than the $99 million loss in the prior-year quarter. Adjusted EBITDA reached $155 million, supported by strong product launches and operational efficiencies. Adjusted diluted EPS was $0.12 compared to $0.14 in Q4 2023.

Amneal Pharmaceuticals received U.S. FDA approval for CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT is designed to provide a longer duration of 'Good On' time with less frequent dosing compared to immediate-release CD/LD. The commercial launch is planned for September 2024.

Amneal Pharmaceuticals, Inc. announced strong first quarter 2024 results, with net revenue of $659 million, an 18% increase compared to the first quarter of 2023. All three segments experienced double-digit top-line growth. The company reached a settlement in principle on a nationwide opioids settlement and affirmed its 2024 full year guidance.

Amneal reported a 1% increase in net revenue to $617 million for Q4 2023. However, the company experienced a GAAP net loss of $99 million, and an adjusted diluted EPS of $0.14.

Amneal Pharmaceuticals reported a strong Q3 2023 with a 14% increase in net revenue to $620 million and a 22% increase in adjusted EBITDA to $154 million. Net income attributable to Amneal Pharmaceuticals, Inc. was $10 million, compared to a net loss of $3 million in the third quarter of 2022. Diluted EPS was $0.06, and adjusted diluted EPS was $0.19. The company affirmed its previously announced increased full-year guidance.

Amneal Pharmaceuticals, Inc. reported net revenue of $599 million for Q2 2023, a 7% increase compared to Q2 2022. GAAP net income was $12 million, with diluted EPS of $0.08. The company raised its full year 2023 guidance, expecting continued growth across its diversified portfolio.

Amneal Pharmaceuticals reported a strong start to 2023 with a 12% increase in net revenue to $558 million compared to the first quarter of 2022. The company's performance was driven by growth across all three business segments. While the company reported a net loss of $7 million, adjusted EBITDA increased by 16% to $116 million. The company is affirming its full year 2023 guidance.

Amneal Pharmaceuticals reported a mixed Q4 2022, with increased net revenue but a net loss according to GAAP. Adjusted EBITDA and EPS showed strong growth, driven by new product launches, expansion of the AvKARE channel, and strong specialty product performance. The company provided 2023 financial guidance, expecting continued revenue and adjusted EBITDA growth.

Amneal Pharmaceuticals reported its Q3 2022 financial results with net revenue of $546 million, a GAAP net loss of $3 million, and an adjusted EBITDA of $126 million. The company is maintaining its full year 2022 outlook.

Amneal Pharmaceuticals reported net revenue of $559 million, a 5% increase compared to Q2 2021. The company experienced a net loss of $121 million, which included a pre-tax charge of $263 million related to the Opana ER® antitrust litigation settlement. Adjusted EBITDA was $135 million, a 6% decrease compared to the previous year, while adjusted diluted EPS was $0.19, down from $0.23 in Q2 2021.

Amneal Pharmaceuticals reported a 1% increase in net revenue to $498 million for Q1 2022 compared to $493 million in Q1 2021. However, the company experienced a net loss of $2 million, a decrease compared to the net income of $7 million in the same quarter of the previous year. Adjusted diluted EPS was $0.12, down from $0.17 in Q1 2021. The company is maintaining its full-year 2022 financial outlook.

Amneal Pharmaceuticals, Inc. reported Q4 2021 net revenue of $537 million, a GAAP net loss of $6 million, and an adjusted diluted EPS of $0.18. The company's performance was driven by generic new product launches and growth in promoted specialty products.

Amneal reported a solid third quarter with net revenue of $529 million, a net loss of $4 million, and adjusted diluted EPS of $0.21. The company is updating its full year financial outlook, including raising adjusted EBITDA and adjusted EPS guidance. They also announced the acquisition of Puniska Healthcare.

Amneal Pharmaceuticals reported a strong second quarter in 2021, with net revenue reaching $535 million, a 15% increase compared to the second quarter of 2020. The company's GAAP net income was $15 million, a significant improvement from the net loss of $12 million in the same period last year. Adjusted EBITDA was $151 million, up 50% year-over-year, and adjusted diluted EPS was $0.25, a 92% increase.

Amneal Pharmaceuticals reported a net revenue of $493 million for Q1 2021, a slight decrease of 1% compared to the previous year. The company's GAAP net income was $7 million, with a diluted income per share of $0.04. Adjusted EBITDA stood at $126 million, and adjusted diluted EPS was $0.20. The company is maintaining its full year 2021 financial outlook.

Amneal Pharmaceuticals reported a 28% increase in net revenue to $510 million for Q4 2020. The company experienced a net loss of $3 million, an improvement from the $32 million loss in the same quarter of the previous year. Adjusted diluted EPS was $0.14, compared to $0.08 in the prior year.

Amneal Pharmaceuticals, Inc. reported a net revenue of $519 million for Q3 2020, a 37% increase compared to Q3 2019. The company's GAAP net loss was $(9) million, with a diluted loss per share of $(0.06). Adjusted net income was $49 million, with an adjusted EBITDA of $114 million and adjusted diluted EPS of $0.16.

Amneal Pharmaceuticals reported a net revenue of $465 million for Q2 2020, a 15% increase compared to Q2 2019. The company's GAAP net loss was $(12) million, and adjusted EBITDA was $101 million. Adjusted diluted EPS was $0.13.

Amneal Pharmaceuticals reported a solid operational and financial performance in Q1 2020, with net revenue of $499 million, a 12% increase compared to Q1 2019. GAAP net income was $115 million, and adjusted EBITDA was $134 million, a 20% increase year-over-year. The company is maintaining its full-year 2020 financial outlook.

Amneal Pharmaceuticals reported a decrease in net revenue and earnings for Q4 2019 compared to the prior year period. Net revenue was $397 million, a decrease of 20%. Net loss was $32 million, and diluted EPS was a loss of $0.23. Adjusted EBITDA was $81 million, and adjusted diluted EPS was $0.08.